Mabwell (Shanghai) BioScience completes RMB1.97 billion Series A financing

The biopharmaceutical company Mabwell (Shanghai) BioScience announced that it has completed 1.97 billion yuan in Series A financing.
Shiyu Capital led the investment, and institutions such as Oriental Fortune Capital, Loyal Valley Capital, and Haitong Capital followed.

The biopharmaceutical company Mabwell (Shanghai) BioScience announced that it has completed 1.97 billion yuan in Series A financing.

Shiyu Capital led the investment, and institutions such as Oriental Fortune Capital, Loyal Valley Capital, and Haitong Capital followed.

According to the introduction of Mabwell (Shanghai) BioScience, the funds raised will be used for the research and development and industrialization of innovative products.

Its research and development focuses on therapeutic monoclonal antibodies, long-acting recombinant proteins and several other macromolecular innovative drugs in subdivided technical fields.

Maiwei (Shanghai) Biotechnology Co., Ltd. is an innovative biopharmaceutical company established in Shanghai Zhangjiang Science City.

The company has a high-throughput antibody drug discovery platform that is in line with international standards, a complete pharmaceutical research system and mature process development capabilities, R&D and production.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/04/29/mabwell-shanghai-bioscience-completes-rmb1-97-billion-series-a-financing/.

Leave a Reply

Please Login to Comment